Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
about
Structural Analysis of Specific Metal Chelating Inhibitor Binding to the Endonuclease Domain of Influenza pH1N1 (2009) PolymeraseBinding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometryA mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal modelEffects of influenza antivirals on individual and population immunity over many epidemic waves.Drug resistance in influenza A virus: the epidemiology and management.New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusionIn vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Swine-origin influenza-virus-induced acute lung injury: Novel or classical pathogenesis?Antiviral strategies for pandemic and seasonal influenzap53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus.Rethinking approaches to improve the utilization of nucleic acid amplification tests for detection and characterization of influenza A in diagnostic and reference laboratories.Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1)Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patientsPeramivir for the treatment of influenza.A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infectionThe host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domainsA replication-incompetent PB2-knockout influenza A virus vaccine vector.Inhibition of influenza virus via a sesquiterpene fraction isolated from Laggera pterodonta by targeting the NF-κB and p38 pathways.A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicitiesAntiviral strategies against influenza virus: towards new therapeutic approaches.Ribavirin attenuates the respiratory immune responses to influenza viral infection in mice.Monoclonal antibodies targeting the synthetic peptide corresponding to the polybasic cleavage site on H5N1 influenza hemagglutinin.Parainfluenza Virus in the Hospitalized Adult.Design of Multivalent Inhibitors for Preventing Cellular Uptake.Novel oral anti-influenza drug candidate AV5080.The emerging influenza virus threat: status and new prospects for its therapy and control.Inhibition of influenza H5N1 invasion by modified heparin derivativesTreatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell TransplantationEleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation
P2860
Q27671365-43C6B196-6AAC-4781-BD52-DB58336BCF3FQ28292279-66CD718E-A3D3-4A3D-9C90-DB8D3E8D068AQ28477927-96ABB6BD-0F61-43E7-9634-899F9A958B8EQ30224681-F382AA59-ABF3-4187-8D56-917111DEB6C6Q30234600-E6CB4B74-73B0-4935-894D-AAD6EB2C7466Q30355297-57A5E4DD-3B8B-48C5-AAEF-77AE70169D53Q30356466-AD4F69ED-C4AF-42A6-9348-AE57A1F7B8EDQ30402300-BD2C88FF-6895-4532-B513-EDA95F934250Q30408116-F90F8022-8DCA-4E21-AD36-27A2EC07C2DEQ30409798-9A2535CA-AC04-4E55-9126-2131365795C7Q30410029-57D3E872-C365-4544-9F71-92DCC4544673Q30412126-60A4628D-0639-4649-AF4A-DF5E9D4046ECQ30412678-1AB84F64-B9F4-4439-99BC-E8B5DFE2533DQ30413154-B183FE9D-2D14-4DC6-AAAE-3A14583FBC01Q30422034-97D7137C-8138-4C11-B7C4-C6ECB14640BCQ34106660-A2865743-006A-4F4E-9BE8-7D85846F3E6DQ35868034-BFE3E61F-6D6B-4CBB-BCD1-40E3CF049498Q36243179-D742F7CE-3C39-4BB3-8CFA-DFB4A8E4FE3EQ36661794-043ACFB9-CBE0-4EB4-B325-7B6617FF177EQ38202012-3B82C26E-2D05-4887-BF42-FC768AB743ECQ39178651-4F1F5DCF-20BB-42BC-BCDF-35860BFFCD0FQ39370136-D7E0E9DE-FB81-4732-B202-AE58DFAAB5BBQ40168808-8FF135D6-F3BE-4AF3-B8D1-3E7E733E85C1Q41718288-3529AC8D-B4C2-4E31-B2CC-AC2829DDB94EQ42224737-013D8311-B64D-4223-BBD4-81A857244E5BQ47555634-A664AC89-FA16-4C3C-8040-5015343EEB6FQ56833667-70B82488-7D9A-4629-91F6-1884FCCEF21CQ57053316-9EEA1AE3-561F-4E15-A084-CC2E11AA30CDQ58758066-A693F970-CC57-42A3-B3B1-3DBA72FC4E3E
P2860
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
@ast
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
@en
type
label
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
@ast
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
@en
prefLabel
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
@ast
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
@en
P2093
P2860
P356
P1476
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
@en
P2093
Richard T Davey
Ronald B Moss
Roy T Steigbigel
P2860
P304
P356
10.1093/JAC/DKQ100
P407
P577
2010-04-07T00:00:00Z